We scan new podcasts and send you the top 5 insights daily.
Because the cornea is an avascular structure that recycles completely within three weeks, treatment pauses provide adequate time for tissue healing. Clinicians recommend prioritizing treatment delays over dose reductions to maintain full dose intensity while allowing ocular side effects to resolve.
For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.
Clinicians mitigate Belantamab's ocular toxicity by extending dosing intervals to every 8-12 weeks. This is effective due to the drug's long half-life and often allows vision to recover between doses, sometimes even deepening responses without sacrificing disease control.
Microcystic keratopathy from belantamab mafodotin involves superficial corneal epithelial changes rather than posterior chamber damage. Lengthening treatment intervals to every 8 to 12 weeks and delaying doses allows vision to recover while maintaining deep, MRD-negative therapeutic responses.
Due to significant ocular toxicity affecting most patients, the approved starting dose for belantumab is likely not optimal long-term. Effective management requires clinicians to proactively hold, delay, and reduce doses at the first sign of side effects, meaning real-world application will differ from the initial protocol.
Data from the DREAM 7 trial reveals that holding belantamab doses for 12 weeks or longer to manage ocular toxicity did not negatively impact progression-free survival (PFS). Responding patients often maintain their response, challenging the conventional wisdom that strict dosing schedules are paramount for efficacy.
GYN oncology nurses are accustomed to GI and hematologic side effects. With mirvetuximab, they must now manage eye-related issues, requiring patient education on prophylactic eye drops and coordination with ophthalmologists for regular exams.
Clinicians are successfully managing Belantamab's primary side effect, keratopathy, by using lower starting doses and extending dosing intervals to every 8 or 12 weeks once a response is seen. This maintains efficacy while significantly improving tolerability for patients.
When managing ocular toxicity from the ADC mirvetuximab, clinicians advocate for delaying the subsequent dose to allow the cornea to heal naturally. This approach is often preferred over an immediate dose reduction, which might unnecessarily compromise the treatment's efficacy.
The onset of ocular symptoms from mervituximab is highly predictable, almost always starting between days 10 and 14 of the second treatment cycle. Proactively warning patients about this specific timeline can reduce their anxiety if and when symptoms appear.
For managing the ocular toxicity associated with the ADC mirvetuximab, an optometrist is a sufficient and often more accessible alternative to an ophthalmologist. This practical insight simplifies care logistics for patients and oncology practices, improving access to necessary monitoring.